Loading...
The proposed 2023 diagnostic criteria for myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD) require the occurrence of one of the core clinical attack types (e.g., optic neuritis, myelitis, or acute demyelinating encephalomyelitis) as well as positive MOG IgG antibodies, and the absence of aquaporin 4-IgG antibodies plus supporting clinical or MRI features when no antibodies are detected (NEJM JW Neurol Mar 27 2023 and Lancet Neurol 2023; 22:268). These criteria would benefit from validation in different cohorts. In this retrospective analysis, investigators included 539 patients tested for MOG antibodies from 2018 through 2022 and were seen at a demyelinating diseases clinic. Median follow-up was 3.6 years.
The proposed…